Carolyn Alonso, MD
Infectious Disease · Boston, MANPI 1841336039
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Pfizer at 43.2% of the total. 2023 is the largest year on record at $5,345, 4.7 times the $1,138 reported in 2021.
Across 7 payments — averaging $1158.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- Merck$3K
- Ferring Pharmaceuticals Inc.$2K
Across 10 payments — averaging $32,876 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$198K
- Merck$103K
- Seres Therapeutics, Inc.$16K
- Astrazeneca UK Limited$11K
What the payments were for
- Consulting fees$2,76634%
- Speaking & faculty fees$3,50043%
- Travel & lodging$1,00112%
- Food & beverage$1952%
- Education$6508%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $3,500 |
| Merck | 2 | $2,766 |
| Ferring Pharmaceuticals Inc. | 4 | $1,845 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REBYOTA$1,845
How this compares
$8,111 in reported general payments places this provider in the 85th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 27 | $104,403 |
| JulucaDolutegravir/Rilpivirine | 27 | $99,491 |
| Fosfomycin Tromethamine | 11 | $2,333 |
| Atovaquone | 16 | $2,303 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $189 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Boston
- Yoav GolanBoston$1.1M
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.